Skip to content

Insider · CIK 0001327111

Lynn Seely

directorceopresidentofficer

Files at BPMC (Blueprint Medicines Corp), LYEL (Lyell Immunopharma, Inc.). First filing Aug 13, 2025, latest Nov 12, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $91k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

LYEL: Lyell Immunopharma, Inc.

LYELOct 9, 2026 · close 8.71

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
40Moderate
LYELsell 4
Lyell Immunopharma, Inc.
$6,637
412 shares
-1%+127% from low-27% from high
48Moderate
LYELsell 4
Lyell Immunopharma, Inc.
$77k
7,257 shares
-10%+37% from low-66% from high
40Moderate
LYELsell 4
Lyell Immunopharma, Inc.
$8,313
797 shares
-2%+36% from low-66% from high

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Nov 10, 2025LYEL
Lyell Immunopharma, Inc.
SOpen-market sale
Common Stock
-412$16.11$6,63767,159Nov 12, 2025
Oct 27, 2025LYEL
Lyell Immunopharma, Inc.
AGrant or award
Option (right to buy)derivative
+175,000$0.00$0175,000Oct 29, 2025
Aug 20, 2025LYEL
Lyell Immunopharma, Inc.
AGrant or award
Common Stock
+40,000$0.00$074,828Aug 22, 2025
Aug 21, 2025LYEL
Lyell Immunopharma, Inc.
SOpen-market sale
Common Stock
-7,257$10.54$77k67,571Aug 22, 2025
Aug 11, 2025LYEL
Lyell Immunopharma, Inc.
SOpen-market sale
Common Stock
-391$10.53$4,11635,234Aug 13, 2025
Aug 12, 2025LYEL
Lyell Immunopharma, Inc.
SOpen-market sale
Common Stock
-406$10.34$4,19734,828Aug 13, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Common Stock
-3,902--13,254Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
UTender of shares
Common Stock
-13,254--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-21,818--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-10,909--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-10,909--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-7,500--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-4,875--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-4,500--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-4,500--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-5,300--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-5,300--0Jul 21, 2025
Jul 17, 2025BPMC
Blueprint Medicines Corp
DDisposition to issuer
Stock Option (Right to Buy)derivative
-4,570--0Jul 21, 2025
Jun 18, 2025BPMC
Blueprint Medicines Corp
AGrant or award
Common Stock
+3,902$128.12$500k17,156Jun 24, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Lynn Seely: insider trades and track record | InsiderTell